214 related articles for article (PubMed ID: 11948140)
1. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
4. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
5. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
[TBL] [Abstract][Full Text] [Related]
6. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells.
Way TD; Lee JC; Kuo DH; Fan LL; Huang CH; Lin HY; Shieh PC; Kuo PT; Liao CF; Liu H; Kao JY
J Agric Food Chem; 2010 Mar; 58(6):3356-65. PubMed ID: 20166659
[TBL] [Abstract][Full Text] [Related]
8. Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies.
Montagnani Marelli M; Moretti RM; Dondi D; Limonta P; Motta M
Arch Ital Urol Androl; 1997 Sep; 69(4):257-63. PubMed ID: 9396187
[TBL] [Abstract][Full Text] [Related]
9. Molecular inhibition of phospholipase cgamma signaling abrogates DU-145 prostate tumor cell invasion.
Turner T; Epps-Fung MV; Kassis J; Wells A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2275-82. PubMed ID: 9815625
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice.
Dondi D; Moretti RM; Montagnani Marelli M; Pratesi G; Polizzi D; Milani M; Motta M; Limonta P
Int J Cancer; 1998 May; 76(4):506-11. PubMed ID: 9590126
[TBL] [Abstract][Full Text] [Related]
14. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
Moretti RM; Marelli MM; Dondi D; Poletti A; Martini L; Motta M; Limonta P
J Clin Endocrinol Metab; 1996 Nov; 81(11):3930-7. PubMed ID: 8923840
[TBL] [Abstract][Full Text] [Related]
16. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
Hagan M; Yacoub A; Dent P
Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
Solca FF; Baum A; Langkopf E; Dahmann G; Heider KH; Himmelsbach F; van Meel JC
J Pharmacol Exp Ther; 2004 Nov; 311(2):502-9. PubMed ID: 15199094
[TBL] [Abstract][Full Text] [Related]
20. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
